Flupirtine as Oral Treatment in Multiple Sclerosis

Inclusion Criteria: * Relapsing-remitting MS according to the revised McDonald-Criteria (2005) * EDSS ≤ 4.0 * Stable treatment with Interferon-β1b for at least 6 months * Sufficient birth control (Pearl-Index \<1) Exclusion Criteria: * Any other MS-course than RRMS * Clinically relevant gastrointestinal disease * Clinically relevant pulmonary, cardiological, infectious or CNS-disease * Clinically relevant disease of liver or bile system, pathological value for transaminases, gamma-GT or bilirubin. * Hepatitis (except uncomplicated hepatitis A with complete remission * Clinically relevant dysfunction of kidneys (creatinine \>180 µmol/l) or bone marrow (HB \< 8.5 g/dl, WBC \< 2.5/nl thrombocytes \< 125/nl) * Myasthenia gravis * Oral anticoagulation (phenprocoumon) * Treatment with carbamazepine or paracetamol * Drug or alcohol abuse * Pregnancy or lactation period * Treatment at any time before or during study with complete lymphoradiation, monoclonal antibodies (e.g. anti-CD4, Campath 1H, natalizumab), mitoxantrone, cyclophosphamide, cyclosporin, azathioprine * Treatment within 6 months before randomization with any other immunomodulatory substance than interferon-β1b or intravenous methylprednisolone